If you have any questions about the clinical trials that have been initiated over the last
18 months, or believe you may be eligible, please call our nurse hotline at 1-866-603-6628.
What’s Next
So far this year, the MMRC has
Also this year, the MMRC became
checkpoint therapies restore the
announced three company-sponsored
involved in its first trial to evaluate
T-cells’ ability to effectively detect
trials that are being offered at a
the effects of an agent in patients
and attack cancers cells. Immune
number of sites.
with smoldering multiple myeloma.
checkpoints ultimately are used
Janssen Biotech, Inc.’s daratumumab
to block the immune response and
is an anti-CD38 antibody that is in late
therefore cancer cells use these
stage clinical development for myeloma.
checkpoint pathways to avoid being
This drug has the potential to harness
recognized and killed by the host’s
the body’s immune system to destroy
immune system. Antibodies directed
myeloma tumor cells. Many MMRC sites
against these immune checkpoint
A Phase II clinical trial is studying
Karyopharm Therapeutics, Inc.’s
selinexor, a novel agent, in combination
with low-dose dexamethasone in
highly refractory patients. The MMRF
recognized the potential of selinexor
will be involved. Ohio State University
in 2010, and awarded Karyopharm
Therapeutics, Inc. a Biotech Investment
Award to help advance the drug from
preclinical analysis through the initiation
of clinical testing in patients. In 2014
proteins, like MPDL3280A, allow the
and Sara Canon Research Institute
immune cells to once again recognize
were some of the first MMRC sites to
and destroy the cancer cells. Immune
open and Sagar Lonial, M.D. at Emory
checkpoint antibodies have been
University and Craig Hofmeister, M.D.
approved in other cancer indications.
at The Ohio State University worked
the MMRC launched a Phase I clinical
In this Phase I study, MPDL3280A from
closely with Janssen Biotech, Inc. on the
trial to assess selinexor in combination
Genentech, an anti-PDL1 antibody,
study design for clinical study.
with Kyprolis in relapsed/refractory
will be given in combination with
patients. This trial is targeted for
Last but not least, we opened the
Revlimid to relapsed patients and as
patients who are refractory to prior
first trial within the MMRC focused
a single agent to patients who have
therapies of proteasome inhibitors and
on a class of drugs known as immune
residual disease post-autologous
immunomodulatory drugs.
checkpoint therapies. Immune
stem cell transplant.
MMRF and MMRC support a robust clinical pipeline
Immunotherapies
and Antibodies
Approved
Novel
Targeted
Therapies
Agents
Mechanisms
Doxil
®
Daratumumab
AT7519
Ixazomib
ABT-199
Elotuzumab
GSK21110183
Marizomib
ARRY-520
MPDL3280A (PDL-1)
OSI906
CB-5083
SAR650984
PD0332991
Ibrutinib
Siltuximab
Selinexor
Janssen Diagnostics, LLC, CELLSEARCH®
Circulating Tumor Cell (CTC) Test
D RU G D E VE LO P M E N T
®
Kyprolis
®
Pomalyst
Revlimid
®
®
Thalomid
Velcade
New Diagnostic Approaches
n
Farydak
®
®
Sequenta
n
LymphoSIGHT™
9